Immunotherapy in patients with systemic mycoses a promising adjunct: A promising adjunct

BioDrugs

Volumn 15, Issue 4, 2001, Pages 207-214

  Farmaki, E ^a   Roilides, E ^a  

^a Aristotle University of Thessaloniki   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; COLONY STIMULATING FACTOR 1; CYTOKINE; FLUCONAZOLE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; POSACONAZOLE; VORICONAZOLE;

ADJUVANT THERAPY; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; BONE MARROW TRANSPLANTATION; CANCER THERAPY; CHEMOPROPHYLAXIS; CHRONIC GRANULOMATOUS DISEASE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; IMMUNOTHERAPY; LEUKOCYTE TRANSFUSION; MYCOSIS; MYELOID LEUKEMIA; NEUTROPENIA; NEUTROPHIL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW;

EID: 0034786049     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200115040-00001     Document Type: Review

References (63)

1. Comparison of interferon-gamma, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor for priming leukocyte-mediated hyphal damage of opportunistic fungal pathogens
2. Beneficial effect of recombinant human granulocyte colony-stimulating factor on fungicidal activity of polymorphonuclear leukocytes from patients with AIDS
3. Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and interferon-γ
4. Granulocyte-macrophage colony-stimulating factor and interferon-γ prevent dexamethasone-induced immunosuppression of antifungal monocyte activity against Aspergillus fumigatus hyphae
5. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor
6. Granulocyte-macrophage colony-stimulating factor: A potent activation signal for mature macrophages and monocytes
7. Protection of human polymorphonuclear leukocyte function from the deleterious effects of isolation, irradiation and storage by gamma-interferon and granulocyte colony-stimulating factor
8. Modulation of host defenses by cytokines: Evolving adjuncts in prevention and treatment of serious infections in immunocompromised hosts
9. Effects of macrophage colony-stimulating factor on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus
10. Effects of granulocyte colony-stimulating factor and interferon-γ on antifungal activity of human polymorphonuclear neutrophils against pseudohyphae of different medically important Candida species
11. Interleukin-4 suppresses antifungal activity of human mononuclear phagocytes against Candida albicans in association with decreased uptake of blastoconidia
12. Interleukin-10 suppresses phagocytic and antihyphal activities of human neutrophils
13. Interleukin- 12 but not interferon-gamma production correlates with induction of T helper type-1 phenotype in murine candidiasis
14. Interleukin-15 augments superoxide production and microbicidal activity of human monocytes against Candida albicans
15. Protective effect of human granulocyte colony-stimulating factor on Cryptococcus and Aspergillus infections in normal and immunosuppressed mice
16. Effects of granulocyte and granulocyte-macrophage colony-stimulating factors in a neutropenic murine model of trichosporonosis
17. Recombinant murine granulocyte colony-stimulating factor protects against acute disseminated Candida albicans infection in non-neutropenic mice
18. Recombinant murine granulocyte-macrophage colony-stimulating factor augments neutrophil recovery and enhances resistance to infections in myelosuppressed mice
19. Macrophage colony-stimulating factor in murine candidiasis: Serum and tissue levels during infection and protective effect of exogenous administration
20. Human recombinant macrophage colony stimulating factor (M-CSF) augments pulmonary host defense against Aspergillus fumigatus
21. Recombinant interferon-γ enhances resistance to acute disseminated Candida albicans infection in mice
22. In vivo immune responses to Candida albicans modified by treatment with recombinant murine gamma interferon
23. Interleukin-4 causes susceptibility to invasive aspergillosis through suppression of protective type 1 responses
24. Antifungal type 1 responses are upregulated in IL-10-deficient mice
25. Role of TNF-alpha in pulmonary host defense in murine invasive aspergillosis
26. Recommendations for use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
27. Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy
28. Randomized, double-blind, placebo-controlled phase III study of recombinant human granulocyte-macrophage colony-stimulating factor, as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas
29. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years) with acute myelogenous leukemia: A study by the Eastern Cooperative Oncology Group (E1490)
30. Treatment of acute myeloid leukemia with cytokines: Effect on duration of neutropenia and response to infections
31. A randomized, double-blind, placebo-controlled, phase III study of Filgrastin in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia
32. Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor
33. Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia
34. Human urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia: A double-blind controlled study
35. Retrospective analysis of infectious disease in patients who receive recombinant human granulocyte-macrophage colony-stimulating factor versus patients not receiving a cytokine who underwent autologous bone marrow transplantation for treatment of lymphoid cancer
36. Successful treatment of a Trichosporon beigelii septicemia in a granulocytopenic patient with amphotericin B and granulocyte colony-stimulating factor
37. Successful treatment of disseminated zygomycosis in a neutropenic patient with amphotericin B lipid complex and granulocyte colony-stimulating factor
38. Role of granulocyte colony-stimulating factor in the management of infection with Fusarium oxysporum in a neutropenic child
39. Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer
40. A double-blind, randomized, placebo-controlled phase II study of Filgrastim (recombinant granulocyte colony-stimulating factor) in combination with fluconazole for treatment of invasive candidiasis and candidemia in nonneutropenic patients
41. Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: A retrospective analysis
42. Comparison of neutrophil and monocyte function by microbicidal cell-kill assay in patients with cancer receiving granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, or no cytokine after cytotoxic chemotherapy
43. Cost effectiveness of amphotericin B plus G-CSF compared with amphotericin B monotherapy. Treatment of presumed deep-seated fungal infection in neutropenic patients in the UK
44. Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon gamma
45. In vivo interferon-Á therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae
46. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease
47. Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin-B
48. Disseminated infection due to Chrysosporium zonatum in a patient with chronic granulomatous disease and review of non-Aspergillus infections in these patients
49. The clinical response to interferon-gamma in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus
50. Myeloid colony-stimulating factors. Use in the newborn
51. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: Results of a randomized, multicenter, controlled trial
52. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis
53. Modulation of neutrophil-mediated activity against the pseudohyphal form of C. albicans by granulocyte colony-stimulating factor administered in vivo
54. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: A pilot study
55. Leucocyte transfusions from rhG-CSF or prednisolone stimulated donors for treatment of severe infections in immunocompromised neutropenic patients
56. Activity of voriconazole, a new triazole, combined with neutrophils or monocytes against Candida albicans: Effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor
57. Activity of voriconazole combined with neutrophils or monocytes against Aspergillus fumigatus: Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor
58. Amphotericin μ lipid complex synergizes with pulmonary alveolar macrophages to destroy conidia of A. fumigatus
59. Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: Role of immune suppression
60. Therapeutic efficacy of human macrophage colony-stimulating factor, used alone and in combination with antifungal agents, in mice with systemic Candida albicans infection
61. Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon
62. Antifungal activity of elutriated human monocytes against Aspergillus fumigatus hyphae: Enhancement by granulocyte-macrophage colony-stimulating factor and interferon-γ
63. Interferon gamma and granulocyte-macrophage colony-stimulating factor for the treatment of hepatosplenic candidosis in patients with acute leukemia